DE60106905D1 - Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp - Google Patents

Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp

Info

Publication number
DE60106905D1
DE60106905D1 DE60106905T DE60106905T DE60106905D1 DE 60106905 D1 DE60106905 D1 DE 60106905D1 DE 60106905 T DE60106905 T DE 60106905T DE 60106905 T DE60106905 T DE 60106905T DE 60106905 D1 DE60106905 D1 DE 60106905D1
Authority
DE
Germany
Prior art keywords
formulations
cell phenotype
malignant cell
nitrogen monoxide
mimetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60106905T
Other languages
English (en)
Other versions
DE60106905T2 (de
Inventor
A Adams
H Graham
Jeremy P W Heaton
Lynne-Marie Postovit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Original Assignee
Cellegy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellegy Pharmaceuticals Inc filed Critical Cellegy Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60106905D1 publication Critical patent/DE60106905D1/de
Publication of DE60106905T2 publication Critical patent/DE60106905T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60106905T 2000-04-26 2001-04-26 Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp Expired - Lifetime DE60106905T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19975700P 2000-04-26 2000-04-26
US199757P 2000-04-26
US27746901P 2001-03-21 2001-03-21
US277469P 2001-03-21
PCT/CA2001/000566 WO2001080890A2 (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype

Publications (2)

Publication Number Publication Date
DE60106905D1 true DE60106905D1 (de) 2004-12-09
DE60106905T2 DE60106905T2 (de) 2005-12-01

Family

ID=26895114

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60106905T Expired - Lifetime DE60106905T2 (de) 2000-04-26 2001-04-26 Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp

Country Status (12)

Country Link
US (1) US6946484B2 (de)
EP (1) EP1278547B1 (de)
JP (1) JP2003531179A (de)
AT (1) ATE281177T1 (de)
AU (2) AU2001250221B2 (de)
CA (1) CA2407466C (de)
DE (1) DE60106905T2 (de)
ES (1) ES2232613T3 (de)
HK (1) HK1052468B (de)
IL (2) IL152428A0 (de)
MX (1) MXPA02010551A (de)
WO (1) WO2001080890A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
AU2003208228A1 (en) * 2002-03-06 2003-09-16 Cellegy Pharmaceuticals, Inc Formulations and methods of using nitric oxide mimetics in cancer treatment
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
US20050096370A1 (en) * 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
ES2294543T3 (es) 2003-07-09 2008-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
SE0401871D0 (sv) * 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
CA2580795A1 (en) * 2004-09-22 2006-04-06 Tripath Imaging, Inc. Methods and compositions for evaluating breast cancer prognosis
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
WO2006128121A2 (en) 2005-05-27 2006-11-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US20070172847A1 (en) * 2005-11-15 2007-07-26 The Regents Of The University Of California Molecular signaling pathways triggered by rituximab: prognostic, diagnostic, and therapeutic uses
US20070202155A1 (en) * 2006-02-03 2007-08-30 Cure Therapeutics, Inc. Low dose no donor-containing transdermal patch
WO2007123777A2 (en) * 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US20070259026A1 (en) * 2006-04-20 2007-11-08 Robert Ang Vasodialating dressing for use with intravenous catheters
US8766512B2 (en) * 2009-03-31 2014-07-01 Sand 9, Inc. Integration of piezoelectric materials with substrates
US20100221247A1 (en) * 2008-09-29 2010-09-02 Robert Bender Agents and methods for treatment of cancer
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
EP2467173B8 (de) 2009-08-21 2019-06-19 Novan, Inc. Wundverbände, verfahren zu ihrer anwendung und verfahren zu ihrer herstellung
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2658979B1 (de) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Zusammensetzungen mit natriuretischen peptiden und verwendungsverfahren dafür
WO2012118042A1 (ja) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
USD949597S1 (en) 2014-06-15 2022-04-26 Bengt Johansson Flooring guard for pets
USD974802S1 (en) * 2013-06-16 2023-01-10 Bengt Johansson Flooring guard for pets
USD975470S1 (en) * 2014-06-15 2023-01-17 Bengt Johansson Flooring guard for pets
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
ES2931337T3 (es) * 2014-07-31 2022-12-28 Univ Western Australia Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red
CA2957552C (en) * 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (de) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa zur behandlung von tracheobronchomalazie
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
EP3773684A1 (de) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Herstellung von glycoproteinen
CN113975264A (zh) * 2018-04-16 2022-01-28 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5840759A (en) * 1993-10-08 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
EP0722320B1 (de) * 1993-10-08 2000-07-19 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Verwendung von stickstoffoxid freisetzenden verbindungen als arzneimittel zur strahlungssensibilisation fur hypoxische zellen
US5700830A (en) * 1994-11-22 1997-12-23 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
LV11542B (en) 1995-03-30 1997-02-20 Latvijas Organiskas Sintezes Instituts Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof
US6153186A (en) 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US5849790A (en) 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
DE19732323C2 (de) * 1996-08-06 1999-08-19 Dunzendorfer Medikamentenkombination zur erhöhten Wirkstoffkonzentration in Geweben
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
EP2292630B1 (de) 1996-09-27 2015-11-25 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services O2-substituierte 1-(2-carboxylato)pyrrolidin-1-yl Diazen-1-ium-1,2-Diolate
AU8398398A (en) 1997-07-14 1999-02-10 Brigham And Women's Hospital Modification of nitric oxide activity to treat fas-induced pathologies
EP1060174B1 (de) 1997-12-23 2004-09-22 Amersham Health AS Stickstoffoxid freisetzende chelatbildner und ihre therapeutische verwendung
CA2330628A1 (en) 1998-05-01 1999-11-11 Queen's University At Kingston Method for diagnosing a vascular condition
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6235782B1 (en) 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
WO2000051597A1 (en) 1999-03-05 2000-09-08 Merck Frosst Canada & Co. Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
US6171620B1 (en) 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
AU2001233052A1 (en) 2000-01-26 2001-08-07 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
SE0000303D0 (sv) * 2000-01-31 2000-01-31 Xylogen Ab Novel compounds
JP2003527209A (ja) 2000-03-20 2003-09-16 ノボバスキュラー インコーポレーテッド 一酸化窒素供与体及び還元剤を含有するマトリックス並びにその使用
US20010038832A1 (en) 2000-04-11 2001-11-08 Benjamin Bonavida Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use

Also Published As

Publication number Publication date
IL152428A0 (en) 2003-05-29
DE60106905T2 (de) 2005-12-01
AU2001250221B2 (en) 2006-07-06
WO2001080890A2 (en) 2001-11-01
HK1052468A1 (en) 2003-09-19
HK1052468B (zh) 2005-06-03
CA2407466A1 (en) 2001-11-01
EP1278547B1 (de) 2004-11-03
ES2232613T3 (es) 2005-06-01
CA2407466C (en) 2010-11-02
AU5022101A (en) 2001-11-07
WO2001080890A3 (en) 2002-08-08
EP1278547A2 (de) 2003-01-29
MXPA02010551A (es) 2003-09-25
US6946484B2 (en) 2005-09-20
IL152428A (en) 2011-06-30
ATE281177T1 (de) 2004-11-15
JP2003531179A (ja) 2003-10-21
US20020040059A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
DE60106905D1 (de) Formulierungen und verfahren zur verwendung von stickstoffmonoxid mimetika gegen einen malignen zellphänotyp
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
ATE499098T1 (de) Verwendung von parp-1-hemmern
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
MX2007003470A (es) Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa.
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
BR9707233A (pt) Fenantridinas
ID29070A (id) Fenilfenantridina dengan aktifitas pencegah pde-iv
MXPA02011411A (es) Inhibidores de proteasa de serina.
SE0301882D0 (sv) New use I
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
DK1313508T3 (da) Kombination indeholdende et antifolat og methylkmalonsyresænkende middel
ATE319718T1 (de) Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore
ATE294793T1 (de) Phenantrhridin-n-oxides mit pde-iv hemmender wirkung
ATE356810T1 (de) Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
DE59909760D1 (de) Benzonaphthyridin-n-oxide mit pde3 und pde4 inhibierender aktivität
ATE315029T1 (de) 6-arylphenanthridine mit pde-iv hemmender wirkung
TR200201150T2 (tr) Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod.
SI1147087T1 (en) Phenanthridine-n-oxides with pde-iv inhibiting activity
DE69628743D1 (de) Levobupivacain und dessen verwendung als anästhetikum bei schwangeren frauen
ATE335824T1 (de) Isolierte luziferasen sowie deren verwendung
EP1303520A4 (de) Therapeutische verbindungen und verfahren
AU6986201A (en) Renal regulatory elements and methods of use thereof
DE60216920D1 (en) Tryptase-inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: QUEEN'S UNIVERSITY AT KINGSTON, KINGSTON, ONTARIO,